Salt Lake City, United States
Recursion (NASDAQ: RXRX) is at the forefront of the TechBio sector, leveraging its platform, Recursion OS, to harness advanced AI and machine learning in pursuit of transforming medicine. Founded in 2013 and headquartered in the United States, Recursion is ambitiously decoding biology with the aim of radically improving lives.
By maintaining one of the world’s largest proprietary biological and chemical datasets, Recursion has positioned itself to identify untapped opportunities in life sciences. Through its massive experimental capacity, conducting up to millions of wet lab experiments weekly, and operating a powerful supercomputer, Recursion achieves insights into trillions of relationships in biology and chemistry.
A founding member of BioHive in Salt Lake City, Recursion's global presence includes offices in Montréal, New York, London, and Oxford. The company recently secured a Post IPO Equity investment from Ark Invest on 01 December 2025, underscoring investor confidence in Recursion’s groundbreaking approach.
